US releases preliminary list of $2 generic drugs for Medicare recipients
Biogen fills in some of the blanks on its trial of a high-dose version of Spinraza
Roche CEO: breast cancer pill could enter $12 bln market if trials succeed
Sage continues downslide as Alzheimer’s study fails
*please scroll down for all the latest news*
